Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

27. Oktober 2026 aktualisiert von: Astellas Pharma Global Development, Inc.

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.

Studienübersicht

Detaillierte Beschreibung

This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.

Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.

Studientyp

Interventionell

Einschreibung (Geschätzt)

390

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Quebec
      • Chicoutimi, Quebec, Kanada
        • Rekrutierung
        • Site CA01194
      • Montreal, Quebec, Kanada
        • Rekrutierung
        • Site CA01071
      • Montreal, Quebec, Kanada
        • Rekrutierung
        • Site CA01052
      • Daegu, Südkorea
        • Rekrutierung
        • Site KR01113
      • Seongnam-si, Südkorea
        • Rekrutierung
        • Site KR01063
      • Seoul, Südkorea
        • Rekrutierung
        • Site KR01065
      • Seoul, Südkorea
        • Rekrutierung
        • Site KR01084
      • Kaohsiung City, Taiwan
        • Rekrutierung
        • Site TW01117
    • Arkansas
      • Little Rock, Arkansas, Vereinigte Staaten, 72211
        • Rekrutierung
        • Arkansas Urology
    • California
      • Santa Barbara, California, Vereinigte Staaten, 93105
        • Rekrutierung
        • Samsun Clinic - Ridley-Tree Cancer Center
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80012
        • Rekrutierung
        • Rocky Mountain Cancer Center
    • Delaware
      • Newark, Delaware, Vereinigte Staaten, 19713
        • Rekrutierung
        • Medical Oncology Hematology Consultants
    • Illinois
      • Hinsdale, Illinois, Vereinigte Staaten, 60521
        • Rekrutierung
        • Hope and Healing Clinical Research LLC
      • New Lenox, Illinois, Vereinigte Staaten, 60451
        • Rekrutierung
        • Hope and Healing Clinical Research LLC
      • Niles, Illinois, Vereinigte Staaten, 60714
        • Rekrutierung
        • Illinois Cancer Specialists
    • Indiana
      • Fort Wayne, Indiana, Vereinigte Staaten, 46825
        • Rekrutierung
        • Fort Wayne Medical Oncology and Hematology
    • Michigan
      • Royal Oak, Michigan, Vereinigte Staaten, 48073
        • Rekrutierung
        • Comprehensive Urology
    • Missouri
      • Columbia, Missouri, Vereinigte Staaten, 65201
        • Rekrutierung
        • Missouri Cancer Associates
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Rekrutierung
        • Siteman Cancer Center
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89106
        • Rekrutierung
        • Comprehensive Cancer Centers of Nevada - Southwest
    • New York
      • New York, New York, Vereinigte Staaten, 10029
        • Rekrutierung
        • Icahn School of Medicine at Mount Sinai
    • Ohio
      • Fairfield, Ohio, Vereinigte Staaten, 45014
        • Rekrutierung
        • Oncology Hematology Care Clinical Trials, LLC
    • Oregon
      • Eugene, Oregon, Vereinigte Staaten, 97401
        • Rekrutierung
        • Williamette Valley Cancer Institute and Research Center
      • Tigard, Oregon, Vereinigte Staaten, 97223
        • Rekrutierung
        • Compass Oncology - West
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Rekrutierung
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78705
        • Rekrutierung
        • Texas Oncology
      • Tyler, Texas, Vereinigte Staaten, 75702
        • Rekrutierung
        • Texas Oncology - Northeast Texas
    • Virginia
      • Charlottesville, Virginia, Vereinigte Staaten, 22903
        • Rekrutierung
        • University of Virginia Comprehensive Cancer Center
      • Norfolk, Virginia, Vereinigte Staaten, 23502
        • Rekrutierung
        • Virginia Oncology Associates

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
  • Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
  • Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
  • Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria:

  • Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
  • Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
  • Prior pelvic radiation for any reason
  • Inadequate bladder function
  • Other active malignancies within 3 years prior to randomization
  • Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
  • Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
  • Uncontrolled diabetes
  • Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
  • Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
  • Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
  • Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
  • Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
  • Active keratitis or corneal ulcerations
  • History of autoimmune disease that has required systemic treatment in the past 2 years
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Prior allogeneic stem cell or solid organ transplant
  • Received a live attenuated vaccine within 30 days prior to randomization

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Arm A

Enfortumab vedotin + pembrolizumab (EV + P)

Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.

Andere Namen:
  • • Padcev
  • • ASG-22CE
  • • ASG-22Me

IV infusion on Day 1 of every 3-week cycle up to cycle 17.

Andere Namen:
  • Keytruda
Aktiver Komparator: Arm B

Concurrent Chemoradiotherapy (cCRT)

64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes.

55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only.

40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation.

500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.

Andere Namen:
  • • 5-Fluorouracil
  • • 5-FU

12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.

Andere Namen:
  • • MMC

100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Zeitfenster: Up to approximately 45.5 months

BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause.

Up to approximately 45.5 months
Overall Survival (OS)
Zeitfenster: Up to approximately 60 months

Time from randomization to death due to any cause.

Up to approximately 60 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Bladder-intact Event Free Survival (BI-EFS) by Investigator
Zeitfenster: Up to approximately 45.5 months

BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause.

Up to approximately 45.5 months
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
Zeitfenster: Up to approximately 60 months

cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology.

Up to approximately 60 months
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
Zeitfenster: Up to approximately 60 months]

Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first.

Up to approximately 60 months]
Time to Cystectomy
Zeitfenster: Up to approximately 60 months

The time from randomization to cystectomy.

Up to approximately 60 months
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
Zeitfenster: Up to approximately 60 months

The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first.

Up to approximately 60 months
Cystectomy Free Survival (CFS)
Zeitfenster: Up to approximately 60 months

The time from randomization to cystectomy or death due to any cause, whichever occurs first.

Up to approximately 60 months
Number of Participants with Treatment Emergent Adverse Event (TEAE)
Zeitfenster: From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)

An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state.

From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
Number of Participants with Serious TEAEs
Zeitfenster: From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)

An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Mitarbeiter

Ermittler

  • Studienleiter: Zejing Wang, MD/PhD, Pfizer

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

11. Mai 2026

Primärer Abschluss (Geschätzt)

31. März 2030

Studienabschluss (Geschätzt)

29. Februar 2032

Studienanmeldedaten

Zuerst eingereicht

29. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. April 2026

Zuerst gepostet (Tatsächlich)

4. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

28. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

27. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • C5701009
  • EV-309 (Andere Kennung: Alias Study Number)
  • 2026-525612-34-00 (Ctis)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Beschreibung des IPD-Plans

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren